Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04584528 · ClinicalTrials.gov registry record · NA
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
A NA study of Sickle Cell Disease and Genetic Disease, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 279
- Enrollment target
- 8
- Study locations
NCT04584528: Completed NA study of Sickle Cell Disease and Genetic Disease, sponsored by Duke University.
NCT04584528 is a NA study of Sickle Cell Disease and Genetic Disease that has completed, run by Duke University. The registered enrollment target is 279 participants, roughly in line with the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target. The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04584528, a NA study of Sickle Cell Disease and Genetic Disease, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 279 participants
- Enrollment target
- 8
- Study locations
Study Summary
The overall purpose of this proposed study is to improve management of vaso-occlusive episodes (VOEs) in adult EDs. We aim to implement NHLBI recommendations for VOE treatment by embedding Individualized Pain Plans (IPPs) in the electronic health record (EHR). The EHR-embedded IPP will serve as a record of patients' SCD genotype and will include analgesic medication recommendations developed by the SCD provider. In this project, we will provide access to the IPP for both adult patients with SCD and ED providers. The proposed multisite study will use a pre-post study design, with a core set of mandatory intervention components and strategies for each participating site and optional components and strategies to allow for intervention adaptation to local needs and resources. The EHR-embedded IPP will be available for all adult ED providers to use as their routine practice, and patients will be invited to participate and enroll in the study. We will use a simplified Technology Acceptance Model to explain the use of the IPP and the RE-AIM framework to assess the Reach, Effectiveness, Adoption, Implementation, and Maintenance of the intervention.
Primary Outcome
Three questions from the Adult Sickle Cell Quality of Life Measure (ASCQ-Me) and Quality of Care (QOC) measure will be used to measure the patient perceived quality of ED pain treatment
Conditions Studied
Interventions
- OTHER Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
Study Locations (8)
California
- University of California San Francisco - Oakland
Georgia
- Georgia Regents University - Augusta
Illinois
- University of Illinois - Chicago
Missouri
- Washington University - St Louis
New York
- Icahn School of Medicine at Mount Sinai - New York
North Carolina
- Duke University - Durham
South Carolina
- Medical University of South Carolina - Charleston
Tennessee
- St. Jude's - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2022-10-01 |
| Phase | NA |
What the finished NCT04584528 record still lists
NCT04584528 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target.
The record links to 4 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP) is the first listed.
NCT04584528 lists 8 locations in 8 states (California, Georgia, Illinois).
Frequently Asked Questions
What is clinical trial NCT04584528 about?
NCT04584528 is a clinical study titled "Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease". The overall purpose of this proposed study is to improve management of vaso-occlusive episodes (VOEs) in adult EDs. We aim to implement NHLBI recommendations for VOE treatment by embedding Individualized Pain Plans (IPPs) in the electronic health record (EHR). The EHR-embedded IPP will serve as a re...
What is the current status of trial NCT04584528?
This trial is currently completed. It is a NA study. The enrollment target is 279 participants. The study started on 2020-10-27. Estimated completion is 2022-10-01.
What conditions does trial NCT04584528 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Genetic Disease, Hematologic Diseases, Anemia, Sickle Cell.
What interventions are being tested in trial NCT04584528?
The interventions under investigation include: Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP) (OTHER).
Who is sponsoring clinical trial NCT04584528?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04584528 being conducted?
This trial has 8 study locations across California, Georgia, Illinois, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04584528's enrollment target sits among peer trials
279 24th of 213 higher than 190 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI